NCT05332340 2025-03-07
Safety, Tolerability and Pharmacokinetics (PK) Evaluation of BZ371A, Topically Administered
Biozeus Biopharmaceutical S.A.
Phase 1 Completed
Biozeus Biopharmaceutical S.A.
Biozeus Biopharmaceutical S.A.
Astellas Pharma Inc
Eisai Inc.